Katholieke Universiteit Leuven

Katholieke Universiteit Leuven, Ku Leuven R&d

Remynd

Vib Vzw

Springworks Therapeutics, Inc.

Pierre Fabre Medicament

K. U. Leuven R&d Remynd

Katholieke Universiteit Levun

Arnaud Marchand

Patrick Chaltin

Dorothée Bardiot

Amuri Kilonda

Wim Smets

Gerard Griffioen

Johan Neyts

Kai Dallmeier

Sara Allasia

Mohamed Koukni

Suzanne Kaptein

Tom Van Dooren

Gunter Carlens

Zeger Debyser

Frauke Christ

Marc De Maeyer

Damien Marchand

Arnout Voet

Veronica Rojas De La Parra

Michael McNaughton

Bart Vanderhoydonck

Melanie Reich

El Bachir Kaloun

Karin Thevissen

Thomas Voets

Joris Vriens

Matthias Versele

Aurélie Candi

Jean-Christophe Vanherck

André Welbers

Verónica Rojas De La Parra

Karim Bedjeguelal

Rémi Rabot

Nicolas Rahier

Patrice Mayer

Hugues Bienayme

Bruno Cammue

Philippe Schambel

Stephen L Gwaltney, Ii

Georg Halder

Stéphane Spieser

Philippe Arzel

Sara Alassia

Dorothee Bardiot

Michael Mcnaughton

The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain and inflammatory hypersensitivity. The invention also relates to a method for the prevention or treatment of said TRPM3 mediated disorders.

Heterocycle derivatives for treating TRPM3 mediated disorders

The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.

Tetrahydrobenzoazepinones and related analogs for inhibiting YAP/TAZ-TEAD

2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD

The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

Viral replication inhibitors

The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds. 

This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterized by cytotoxic &#x3b1;-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases

The present invention relates to a series of compounds having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to methods for the preparation of such compounds, as well as to novel intermediates useful in one or more steps of such syntheses. The invention also relates to pharmaceutical compositions comprising an effective amount of such compounds as active ingredients. This invention further relates to the use of such compounds as medicines or in the manufacture of a medicament useful for the treatment of animals suffering from viral infections, in particular HIV infection. This invention further relates to methods for the treatment of viral infections in animals by the administration of a therapeutic amount of such compounds, optionally combined with one or more other drugs having anti-viral activity.

Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors

This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterized by cytotoxic &#x3b1;-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1), wherein R, R, R, R, R, E, n, Y, Y, Y, Y, Y, B, R, and m are as defined in the claims. 

Compounds for the treatment of neurodegenerative diseases

This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic &#x3b1;-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1) wherein R, R, R, R, E, n, Y, Y, Y, Y, Y, L, B, R, and m are as defined in the claims. 

The present invention relates to compounds of formula (A), as further defined herein, having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to pharmaceutical compositions comprising an effective amount of such compounds as active ingredients. The invention further relates to the use of such compounds, optionally combined with one or more other drugs having antiviral activity, for the treatment of animals suffering from viral infections, in particular HIV infection. 

Antiviral compounds

Growing community of inventors

Leuven, Belgium

Arnaud Marchand